Roivant Sciences and Takeda form Myovant Sciences

6 June 2016

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) and Bermuda-based privately-held Roivant Sciences today announced the formation of a new company named Myovant Sciences.

The new biopharmaceutical company will be focused on delivering innovative women's health and prostate cancer solutions by efficiently advancing new medicines to market that have the potential to improve the lives of millions of patients.

In addition, Lynn Seely, an endocrinologist who led the development of Xtandi (enzalutamide) for the treatment of prostate cancer as the chief medical officer of Medivation (Nasdaq: MDVN) from 2005 to 2015, was named the president and chief executive of Myovant Sciences.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK